company background image
0GT logo

Stoke Therapeutics DB:0GT Stock Report

Last Price

€9.30

Market Cap

€277.9m

7D

70.6%

1Y

27.4%

Updated

26 Mar, 2024

Data

Company Financials +

0GT Stock Overview

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States.

0GT fundamental analysis
Snowflake Score
Valuation2/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

Stoke Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Stoke Therapeutics
Historical stock prices
Current Share PriceUS$9.30
52 Week HighUS$12.40
52 Week LowUS$3.16
Beta0.67
1 Month Change93.75%
3 Month Change99.57%
1 Year Change27.40%
3 Year Change-69.41%
5 Year Changen/a
Change since IPO-61.60%

Recent News & Updates

Recent updates

Shareholder Returns

0GTDE BiotechsDE Market
7D70.6%2.1%1.9%
1Y27.4%37.0%7.3%

Return vs Industry: 0GT underperformed the German Biotechs industry which returned 35.8% over the past year.

Return vs Market: 0GT exceeded the German Market which returned 6.4% over the past year.

Price Volatility

Is 0GT's price volatile compared to industry and market?
0GT volatility
0GT Average Weekly Movement23.2%
Biotechs Industry Average Movement5.8%
Market Average Movement4.8%
10% most volatile stocks in DE Market10.1%
10% least volatile stocks in DE Market2.4%

Stable Share Price: 0GT's share price has been volatile over the past 3 months.

Volatility Over Time: 0GT's weekly volatility has increased from 15% to 23% over the past year.

About the Company

FoundedEmployeesCEOWebsite
2014110Ed Kayehttps://www.stoketherapeutics.com

Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels. Its lead clinical candidate is STK-002, which is in preclinical stage for the treatment of autosomal dominant optic atrophy.

Stoke Therapeutics, Inc. Fundamentals Summary

How do Stoke Therapeutics's earnings and revenue compare to its market cap?
0GT fundamental statistics
Market cap€277.89m
Earnings (TTM)-€96.67m
Revenue (TTM)€8.11m

54.3x

P/S Ratio

-4.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
0GT income statement (TTM)
RevenueUS$8.78m
Cost of RevenueUS$0
Gross ProfitUS$8.78m
Other ExpensesUS$113.48m
Earnings-US$104.70m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-2.26
Gross Margin100.00%
Net Profit Margin-1,192.47%
Debt/Equity Ratio0%

How did 0GT perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.